Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
Feature|Videos|July 22, 2025

Delivering What Matters, Together

A new partnership between MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany, and Simtra BioPharma Solutions is delivering streamlined ADC solutions that simplify the supply chain, accelerate patient access to vital treatments, and offer customers expert support.

In this video, industry leaders Mike Schaefers, Chief Commercial Officer at Simtra BioPharma Solutions, and Shiva Khalafpour, Head of CDMO Business at MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany, discuss the objectives of a recent alliance between their companies.

Watch this video and learn more:

  • The motivation and vision behind the MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany, and Simtra BioPharma Solutions partnership
  • How this alliance simplifies the supply chain for clients in the ADC space
  • The specific benefits customers can expect from this integrated approach
  • Insights into the seamless integration of supply chain departments between both companies
  • The crucial role of project managers in ensuring the partnership’s success
  • How the collaboration expedites patient access to life-saving ADC therapies

Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.